Vladimír is a graduate of The University of Economics Prague, Czech Republic, where he studied mathematical method in economics. Later he obtained an MBA degree from De Paul University Chicago.

Prior to joining SOTIO, he was a CFO and held other managerial positions in several multinational companies in the area of services, production and sales & distribution.

He also held for nearly 5 years a managerial position in a consulting company with focus on M&A, restructuring and appraisal. His main area of operation was the CEE region.

Vladimír joined SOTIO  in 2013 as CFO of SOTIO China. In September 2016 he was appointed the CEO of SOTIO Medical Research Co.,Ltd. in China.

路演题目：

在“一带一路”的引领下，舒迪安在国内医药卫生领域寻求更广泛的科研与运营的合作。

路演项目简介：

舒迪安是一家生物技术公司，致力于开发基于活化树突状细胞的新疗法，主要专注于癌症和自体免疫性疾病的治疗。

舒迪安的使命是采用基于自有知识产权的细胞技术来开发新的治疗方法，并通过自有的免疫疗法平台填补现有的医疗需求空缺。

舒迪安的业务活跃于欧洲、中国、美国及俄罗斯。由于其得天独厚的地理位置优势，舒迪安位于布拉格的GMP认证生产基地可为欧洲和美国开展的临床项目提供免疫制剂。

2014年，舒迪安中国实验室在北京建成，目前，此实验室生产的免疫治疗应用于与国内多家顶尖医院合作开展的研究项目。

舒迪安公司隶属于PPF集团，PPF集团是中东欧最大的金融投资集团。更多内容，将于会议中呈现。